Savara Inc. has released a corporate presentation detailing its ongoing efforts to develop new therapies for rare respiratory diseases, with a primary focus on autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The presentation highlights the company's lead investigational candidate, MOLBREEVI (molgramostim inhalation solution), which currently has conditional trade name acceptance from regulatory authorities but is not yet approved for any indication. Savara plans to resubmit a Biologics License Application (BLA) for MOLBREEVI in December 2025, following data that indicate a favorable benefit/risk profile and good tolerability. The presentation also provides insights into the patient journey, emphasizing the challenges of current treatment options such as whole lung lavage and the need for alternative therapies. The executive leadership team and their respective roles are outlined within the document. You can access the full presentation through the link below.